Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmala Biotech Holdings Inc MDXXF


Primary Symbol: C.MDMA

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

Recent & Breaking News (CSE:MDMA)

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Canada NewsWire October 13, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Canada NewsWire October 11, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Canada NewsWire October 6, 2022

PharmAla Biotech to supply University of California Clinical Trial with LaNeo(TM) MDMA

Canada NewsWire October 4, 2022

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo(TM) MDMA

Canada NewsWire August 31, 2022

PharmAla Biotech completes filing of Patent application for 6 MDMA analogs

Canada NewsWire August 29, 2022

PharmAla Biotech to supply Major Australian Research Institute with LaNeo(TM) MDMA for Phase 3 Clinical Trial

Canada NewsWire August 22, 2022

IIROC Trade Resumption - MDMA

Canada NewsWire August 17, 2022

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Canada NewsWire August 17, 2022

IIROC Trading Halt - MDMA

Canada NewsWire August 17, 2022

PharmAla Biotech (CSE:MDMA) to be the exclusive supplier for GMP LaNeo and Engineering MDMA

Brieanna McCutcheon  August 5, 2022

PharmAla Biotech named Exclusive MDMA Supplier to InterVivo Solutions

Canada NewsWire August 5, 2022

PharmAla Biotech Applauds Sen. Cory Booker and Sen. Rand Paul's Bill to Include MDMA in "Right-to-Try" Legislation

Canada NewsWire July 25, 2022

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Canada NewsWire July 4, 2022

PharmAla Biotech Registers Trademark for MDMA

Canada NewsWire June 24, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Canada NewsWire June 2, 2022

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

Canada NewsWire May 19, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Canada NewsWire May 10, 2022

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

Canada NewsWire April 8, 2022

PharmAla Biotech adds David Purcell as Director of Sales

Canada NewsWire March 14, 2022